Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/YCT.0b013e3181710310 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Carvedilol inhibits neuronal hyperexcitability caused by epilepsy-associated KCNT1 mutations.
Br J Pharmacol
January 2025
State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, China.
Article Synopsis
- KCNT1 mutations, like M267T, are linked to epilepsy, and traditional medications are often ineffective for affected patients.
- This study investigated the mutation's effects on neuronal activity and tested carvedilol, an FDA-approved drug, for its ability to reverse the mutation's harmful effects.
- Results showed carvedilol improved channel function and reduced seizure activity in mice, suggesting it may be a promising treatment option for epilepsy related to KCNT1 mutations.
Carvedilol suppresses ryanodine receptor-dependent Ca2+ bursts in human neurons bearing PSEN1 variants found in early onset Alzheimer's disease.
PLoS One
August 2024
Department of Clinical Laboratory Technology, Faculty of Medical Science, Juntendo University, Chiba, Japan.
Seizures are increasingly being recognized as the hallmark of Alzheimer's disease (AD). Neuronal hyperactivity can be a consequence of neuronal damage caused by abnormal amyloid β (Aß) depositions. However, it can also be a cell-autonomous phenomenon causing AD by Aß-independent mechanisms.
View Article and Find Full Text PDFCarvedilol increases seizure resistance in a mouse model of -derived epilepsy.
Front Pharmacol
June 2024
Department of Human Genetics, Emory University, Atlanta, GA, United States.
Article Synopsis
- - Patients with sodium channel mutations experience various symptoms, such as seizures, developmental delays, and motor issues.
- - A study by Atkin et al. identified 90 compounds that reduced sodium influx in cells with a specific mutation, with amitriptyline, carvedilol, and nilvadipine being the most effective.
- - In further tests on mice, amitriptyline and fenfluramine showed strong seizure protection, but only carvedilol significantly helped mice with the specific mutation, suggesting it may be a promising treatment option.
Golimumab-induced posterior reversible encephalopathy syndrome (PRES): a case-based review.
Clin Rheumatol
December 2023
Department of Internal Medicine, Division of Rheumatology, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
Posterior reversible encephalopathy syndrome (PRES) is a neurotoxic state which is characterized by seizures, headache, visual disturbances, paresis, and altered mental status. Golimumab is anti-tumor necrosis factor-α inhibitor (anti-TNF-α) that can be used in the treatment of rheumatologic diseases. Here, we present a patient who had developed PRES after golimumab treatment for ankylosing spondylitis (AS).
View Article and Find Full Text PDFInfluence of carvedilol on anticonvulsant effect of gabapentin.
Acta Neurol Belg
December 2011
I.T.S Paramedical College, Ghaziabad, Uttar Pradesh, India.
The present study was performed to investigate whether or not carvedilol (a beta-adrenoreceptor antagonist) potentiates the anticonvulsive activity of gabapentin against ICES (Increasing current electroshock) and PTZ (Pentylenetetrazole) induced seizures in mice. Further the effect of combination of both the drugs on spatial working memory and locomotor activity on rotarod was also evaluated. The biochemical estimation was done by measuring the lipid peroxidation and reduced glutathione in brain tissue.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!